Andrew Dawson, MD
Neurology · Brooklyn, NYNPI 1093775934
Payments from drug & device makers
Across 193 payments — averaging $214.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$32K
- Livanova USA, Inc.$4K
- SK Life Science, Inc.$2K
- UCB, Inc.$916
- Neuropace, Inc.$450
- Greenwich Biosciences, Inc.$440
- plus $2K from 25 others
What the payments were for
- Speaking & faculty fees$30,68174%
- Travel & lodging$2,8737%
- Food & beverage$7,92119%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 64 | $31,600 |
| Livanova USA, Inc. | 18 | $4,030 |
| SK Life Science, Inc. | 28 | $2,050 |
| UCB, Inc. | 15 | $916 |
| Neuropace, Inc. | 3 | $450 |
| Greenwich Biosciences, Inc. | 3 | $440 |
| Sunovion Pharmaceuticals Inc. | 6 | $328 |
| Eisai Inc. | 10 | $245 |
| Jazz Pharmaceuticals Inc. | 2 | $206 |
| Medtronic | 1 | $178 |
| Neurelis, Inc. | 2 | $174 |
| Immedica Pharma US, Inc. | 1 | $160 |
| Novartis | 8 | $114 |
| Merz North America, Inc. | 2 | $60 |
| Teva Pharmaceuticals USA, Inc. | 4 | $57 |
| Biogen | 3 | $52 |
| CSL Behring | 3 | $51 |
| Grifols USA, LLC | 3 | $50 |
| Avanos Medical | 1 | $44 |
| EMD Serono, Inc. | 3 | $42 |
| Otsuka America Pharmaceutical, Inc. | 2 | $36 |
| Zogenix Inc. | 1 | $30 |
| Lundbeck LLC | 2 | $25 |
| Sanofi | 1 | $22 |
| Alnylam Pharmaceuticals Inc. | 1 | $20 |
| Mallinckrodt Enterprises LLC | 1 | $20 |
| Acadia Pharmaceuticals Inc | 1 | $19 |
| Merz Pharmaceuticals, LLC | 1 | $18 |
| GE HealthCare | 1 | $14 |
| Lilly USA, LLC | 1 | $14 |
| Strongbridge US Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- QULIPTA$18,629
- UBRELVY$12,169
- VNS Therapy$3,572
- Epidiolex$568
- RNS Neurostimulator Kit$450
- APTIOM$250
- VNS - Sentiva$250
- ACTIVA$178
- ZTALMY$160
- VALTOCO$146
- Briviact$125
- Nayzilam$125
- Fycompa$122
- XCOPRI$100
How this compares
$41,476 in reported general payments places this provider in the 80th percentile of 1,623 neurology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Clobazam | 15 | $1,833 |
| Levetiracetam ErLevetiracetam | 14 | $1,674 |
| Levetiracetam | 49 | $668 |
| Lacosamide | 15 | $345 |
| Lamotrigine | 33 | $294 |
| Topiramate | 18 | $189 |
Paid to pharmacies, not to this prescriber.
Other neurology in Brooklyn
- Idan SharonBrooklyn$2.1M
- Christian GrommesNew York$9.9M
- Ilya KisterNew York$9.5M
- E DorseyNew York$8.5M
- Lauren SchaffNew York$8.2M
- Richard HolubAlbany$6.3M
- Martin SadowskiNew York$5.4M
- Lawrence HonigNew York$4.9M
- Laszlo MechtlerAmherst$4.3M
- Bennett MyersAmherst$3.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.